Kessy E, Olotu A
Malar J. 2025; 24(1):33.
PMID: 39893367
PMC: 11786456.
DOI: 10.1186/s12936-025-05277-x.
Kc N, Church L, Riyahi P, Chakravarty S, Seder R, Epstein J
Front Immunol. 2022; 13:1006716.
PMID: 36389797
PMC: 9641621.
DOI: 10.3389/fimmu.2022.1006716.
Kibwana E, Kapulu M, Bejon P
Curr Top Microbiol Immunol. 2022; 445:337-365.
PMID: 35704094
PMC: 7616462.
DOI: 10.1007/82_2022_256.
Odedra A, Mudie K, Kennedy G, Watts R, Rossignol E, Mitchell H
Malar J. 2021; 20(1):43.
PMID: 33446191
PMC: 7807416.
DOI: 10.1186/s12936-021-03581-w.
Stewart L, Diaz-Ingelmo O, Claessens A, Abugri J, Pearson R, Goncalves S
Commun Biol. 2020; 3(1):624.
PMID: 33116247
PMC: 7595149.
DOI: 10.1038/s42003-020-01349-7.
Growth Rate of Plasmodium falciparum: Analysis of Parasite Growth Data From Malaria Volunteer Infection Studies.
Wockner L, Hoffmann I, Webb L, Mordmuller B, Murphy S, Kublin J
J Infect Dis. 2019; 221(6):963-972.
PMID: 31679015
PMC: 7198127.
DOI: 10.1093/infdis/jiz557.
Searching for Improved Flu Vaccines-The Time Is Now.
Atmar R, Keitel W
J Infect Dis. 2019; 221(1):1-4.
PMID: 31665360
DOI: 10.1093/infdis/jiz545.
A bioreactor system for the manufacture of a genetically modified Plasmodium falciparum blood stage malaria cell bank for use in a clinical trial.
Pawliw R, Farrow R, Sekuloski S, Jennings H, Healer J, Phuong T
Malar J. 2018; 17(1):283.
PMID: 30081913
PMC: 6080485.
DOI: 10.1186/s12936-018-2435-x.
Controlled Human Malaria Infection: Applications, Advances, and Challenges.
Stanisic D, McCarthy J, Good M
Infect Immun. 2017; 86(1).
PMID: 28923897
PMC: 5736798.
DOI: 10.1128/IAI.00479-17.
Comparison of statistical models to estimate parasite growth rate in the induced blood stage malaria model.
Wockner L, Hoffmann I, ORourke P, McCarthy J, Marquart L
Malar J. 2017; 16(1):352.
PMID: 28841864
PMC: 5574106.
DOI: 10.1186/s12936-017-1999-1.
Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development.
McCarthy J, Marquart L, Sekuloski S, Trenholme K, Elliott S, Griffin P
Antimicrob Agents Chemother. 2016; 60(6):3669-75.
PMID: 27044554
PMC: 4879391.
DOI: 10.1128/AAC.02883-15.
Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01.
Payne R, Milne K, Elias S, Edwards N, Douglas A, Brown R
J Infect Dis. 2016; 213(11):1743-51.
PMID: 26908756
PMC: 4857475.
DOI: 10.1093/infdis/jiw039.
Cross-species malaria immunity induced by chemically attenuated parasites.
Good M, Reiman J, Rodriguez I, Ito K, Yanow S, El-Deeb I
J Clin Invest. 2013; .
PMID: 23863622
PMC: 4011145.
DOI: 10.1172/JCI66634.
Challenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccines.
Sheehy S, Douglas A, Draper S
Hum Vaccin Immunother. 2013; 9(9):1831-40.
PMID: 23778312
PMC: 3906345.
DOI: 10.4161/hv.25383.
Determining the validity of hospital laboratory reference intervals for healthy young adults participating in early clinical trials of candidate vaccines.
Rowland R, OHara G, Hamill M, Poulton I, Donaldson H, Dinsmore L
Hum Vaccin Immunother. 2013; 9(8):1741-51.
PMID: 23733037
PMC: 3906276.
DOI: 10.4161/hv.24998.
Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity.
Bijker E, Bastiaens G, Teirlinck A, van Gemert G, Graumans W, van de Vegte-Bolmer M
Proc Natl Acad Sci U S A. 2013; 110(19):7862-7.
PMID: 23599283
PMC: 3651438.
DOI: 10.1073/pnas.1220360110.
Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?.
Duncan C, Hill A, Ellis R
Hum Vaccin Immunother. 2012; 8(6):706-14.
PMID: 22508415
PMC: 3495712.
DOI: 10.4161/hv.19712.
Controlled human blood stage malaria infection: current status and potential applications.
Duncan C, Draper S
Am J Trop Med Hyg. 2012; 86(4):561-5.
PMID: 22492136
PMC: 3403771.
DOI: 10.4269/ajtmh.2012.11-0504.
A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs.
McCarthy J, Sekuloski S, Griffin P, Elliott S, Douglas N, Peatey C
PLoS One. 2011; 6(8):e21914.
PMID: 21887214
PMC: 3159571.
DOI: 10.1371/journal.pone.0021914.
Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.
Duncan C, Sheehy S, Ewer K, Douglas A, Collins K, Halstead F
PLoS One. 2011; 6(7):e22271.
PMID: 21799809
PMC: 3142129.
DOI: 10.1371/journal.pone.0022271.